Travelers encouraged to protect themselves from carbon monoxide following recent tragedies
It's an invisible danger you probably aren't thinking about when you're headed on vacation.
The threat of carbon monoxide has been linked to several recent tragedies involving travelers.
14-year-old Miller Gardner, son of former New York Yankees player Brett Gardner, died on a family vacation at a Costa Rica beach resort back in March.
His death happened one month after three young women from Revere were discovered dead in their Belize hotel room.
Authorities said carbon monoxide poisoning caused the deaths in both cases.
'It's not something that we normally see or talk about which is why it's easy to lose track of it,' said Charon McNabb, President of the National Carbon Monoxide Awareness Association.
McNabb has made it her mission to educate travelers on the steps they can take to protect themselves from carbon monoxide poisoning.
'Call ahead, and ask the management, is it possible to have a carbon monoxide alarm? When was the last time the alarm was checked?,' she advised.
McNabb also recommends avoiding stay near the hotel's pool where equipment is often a hotspot for CO leaks.
'If you have small kids I know it's really enticing to have a room next to the pool, but it could be quite dangerous,' she explained.
Rental platforms like Airbnb and VRBO often indicate whether rentals have carbon monoxide alarms installed.
McNabb said even if your accommodation has a carbon monoxide detector, it won't matter if it isn't tested regularly and replaced every few years.
'Carbon monoxide alarms have a 5-to-10-year shelf life. It's very difficult to tell from the front of an alarm how long into the aging process that alarm might be,' said McNabb.
Safe Kids Worldwide suggests families bring a portable carbon monoxide alarm on vacation especially if the location is an older building.
If a carbon monoxide is already present, the organization suggests testing it out.
Boston 25 News found portable CO detectors with good reviews for under $50 on Amazon.
It's important make sure the device you select is certified as meeting standards set by UL Standards & Engagement.
'People can protect themselves by bringing these small devices with them particularly if you have families. Small children and pets are affected as well,' said Dr. Barbarajean Magnani, Professor of Anatomic and Clinical Pathology Emerita at Tufts University School of Medicine.
Dr. Magnani said carbon monoxide can suffocate victims before they know it's too late.
'The problem with carbon monoxide, it's a colorless, odorless and tasteless gas, so people are unaware if there's a problem, if there's a leak,' she said.
Carbon is the leading cause of poisoning deaths in the U.S.
Symptoms may include:
Headache
Dizziness
Nausea
Vomiting
Weakness
Chest pain
Confusion
According to the Centers for Disease Control and Prevention, more than 400 Americans die each year 'from unintentional carbon monoxide poisoning not linked to fires.'
Data from the National Fire Incident Reporting System shows firefighters responded to more than 4,000 carbon monoxide incidents at hotels, motels, and resorts between 1999 and 2020.
More than 1,000 people have been hurt and at least two dozen have died.
The National Conference of State Legislatures says the requirements for carbon monoxide detectors in homes and hotels differ by state.
Not all U.S. states require properties to install CO detectors.
In 2005, Massachusetts passed 'Nicole's Law' which requires that carbon monoxide detectors be installed in all residences that have any source of carbon monoxide.
'It's important for our government officials to recognize the gap in the safety net and try to close that up for our travelers,' added McNabb.
McNabb is working with lawmakers to advocate for 'Safe Stay Act' which will be introduced in June.
The federal bill would require all hotels and motels nationwide to install compliant carbon monoxide detectors and provide written notice of compliance to guests during check-in.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
44 minutes ago
- Newsweek
Can Tackling Addictions Reduce Medicaid Costs?
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Discussions around Medicaid costs have become more heated than ever in recent months as President Donald Trump's administration tries to push its budget bill through the legislative ranks. House Republicans have instructed the House Committee on Energy and Commerce to slash $880 billion in spending over the next decade, with Medicaid making up 93 percent of the committee's budget. As a result, the amount of money the federal Medicaid program needs to provide health care services for more than 70 million Americans has been under dispute, with some arguing there is significant waste and misuse of money in the system, while others have warned cuts would leave millions of vulnerable people without access to health care. While lawmakers continue debating the divisive legislation, experts have discussed with Newsweek whether there could be another way of reducing Medicaid costs—tackling substance use disorders. Medicaid enrollees with substance use disorders require significantly higher health costs than those without—around $1,200 per month on average compared to $550, according to KFF. Around 7.2 percent of Medicaid recipients age 12 to 64 have a diagnosed substance use disorder, and treatment is key to addressing overdoses, deaths and other health or social complications, KFF reported. So could tackling substance use disorders in turn reduce costs for the Medicaid program? Here's what experts told Newsweek. Photo-illustration by Newsweek/Getty/Canva Why Are Medicaid Costs Higher for Those With Substance Use Disorders? The reason Medicaid enrollees with substance use disorders have higher health costs is because they often also have additional health complications, Dr. Joshua Lynch, professor of emergency and addiction medicine at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, New York, told Newsweek. This could be physical health conditions, such as hypertension, high cholesterol and diabetes, or mental health disorders, "which can lead to more complex health care needs," he added. Those with substance use disorders also may "experience more fragmented care and more challenging access to high quality, lower cost care and preventative services," Lynch said. They may also struggle to work, or stay in work, and this may "contribute to increased reliance on higher-cost healthcare services," he added. Many Americans with substance use disorders also go undiagnosed, Brendan Saloner, professor of health policy and management at the John Hopkins Bloomberg School of Public Health, Maryland, told Newsweek. He added that those with substance addiction can have a lot of problems, such as the risk of overdose, or contracting blood-borne diseases like HIV or hepatitis C, as well as other issues, so "it's much better to get people into care proactively then to wait for their problems to become a crisis." The higher costs for those with substance use disorders, therefore, could "reflect the devastating physical consequences of substance use itself," Heidi Allen, professor of social work at the Columbia University School of Social Work, New York, told Newsweek, pointing to overdoses, increased vulnerability for chronic illness and exposure to infectious diseases. It's also not just about health complications, John Kelly, professor of psychiatry at Harvard Medical School and director of the Recovery Research Institute at Massachusetts General Hospital, told Newsweek. "The nature of these disorders means also that, on average, in the Medicaid population, individuals suffering from substance use disorder tend to have more social instability in terms of secure housing, employment, and criminal justice complications. These all contribute to increased costs," he said. Could Tackling Substance Use Disorders Reduce Medicaid Costs? While tackling substance use disorders may not slash Medicaid costs in the short term, as it would require investment in prevention and treatment, it could have positive economic impacts in the long run. "Prioritizing substance use treatment for enrollees might not reduce Medicaid costs in the short term, since we would expect more Medicaid enrollees to engage with treatment, which itself costs money," Allen said. However, she added that "it could certainly improve the health of enrollees, which might result in Medicaid savings down the road." If patients also have access to high-quality treatment and are able to manage their condition, "they have a lower reliance on high-cost health care such as emergency visits and inpatient hospitalizations," Lynch said. He added that other comorbidities also become more manageable, while housing stability and employment turn more achievable. "All of these will lead to a decrease in overall Medicaid spending," he said. Kelly also said he thought that tackling substance use disorders could reduce costs for Medicaid, adding that "focus on earlier intervention, and better implementation of care coordination will result in reduced use of more expensive acute medical care services, as well as prevention of the contraction of more chronic disease such as alcohol-associated liver diseases, HIV and hepatitis infections." "I am very confident that it would help to prevent some long-term costs to the program and would have a huge impact on other non-health needs like employment and reduced incarceration," Saloner said. But he added that whether it fully pays for itself, or saves money, is a more difficult question to answer. "We have some older studies showing that substance use care can offset lots of costs to society, but purely from the perspective of the Medicaid budget it's hard to say. The quality of life gains make it very cost-effective, whether or not it's cost saving," he said. Carrie Fry, professor in the department of health policy at Vanderbilt University School of Medicine, Tennessee, told Newsweek: "Research shows that addressing substance use disorder with effective, evidence-based treatments reduces Medicaid costs." In order to cut Medicaid costs, Fry said, making it easier for people with substance use disorders "to start and remain on effective treatment" would be an important step in the process. "For opioid use disorder, this means expanding availability of medications for opioid use disorder including methadone, buprenorphine, and naltrexone," she said. She added that only about half of Medicaid enrollees with an opioid use disorder receive evidence-based treatment in a given year. "So, treatment is an important first step to addressing the burden of substance use disorders in Medicaid and can reduce or prevent additional downstream costs," Fry said. She added that reducing the prevalence of substance use disorder via prevention will "require a more comprehensive approach to addressing broader social conditions that lead to increased risk of developing a substance use disorder."
Epoch Times
11 hours ago
- Epoch Times
Why Drug Price Reform Alone Won't Heal America
President Donald Trump's revived effort to reduce prescription drug prices is a long-overdue step toward affordability. For millions of Americans, the cost of staying alive has become burdensome, and any policy that eases the burden is worth celebrating. However, as a physician, I've seen what happens when medications become too cheap, plentiful, and automatic. If we don't reform how drugs are used, we risk trading financial hardship for clinical harm. Vagaries of Lower Drug Costs In today's health care system, medication is the first answer—and often the last, especially for older adults. More than 40
Yahoo
17 hours ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
